ReviewCurrent rheumatology reports2013
Chondroitin and glucosamine in the management of osteoarthritis: an update.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials.Rheumatology international · 2018Pooled it
- Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.Scientific reports · 2015Pooled it
- Effects of cartilage-supporting nutritional supplementation on knee osteoarthritis symptoms and quality of life in a 12-week randomized double-blind placebo-controlled pilot study.Scientific reports · 2025Trial
- Trial
- Trial
- Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.Annals of the rheumatic diseases · 2016Trial
- Comprehensive Research Progress on Glucosamine: A Review.Applied biochemistry and biotechnology · 2026Review
- A Highly Active Chondroitin Sulfate Lyase ABC for Enzymatic Depolymerization of Chondroitin Sulfate.Polymers · 2022Article
- Efficient production of D-glucosamine by diacetylchitobiose deacetylase catalyzed deacetylation of N-acetyl-D-glucosamine.Biotechnology letters · 2022Article
- Emerging microfluidics-enabled platforms for osteoarthritis management: from benchtop to bedside.Theranostics · 2022Review
- The P2X7 Receptor in Osteoarthritis.Frontiers in cell and developmental biology · 2021Review
- CS-semi5 Inhibits NF-κB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis.Frontiers in pharmacology · 2021Article
- The Immune Cell Landscape in Different Anatomical Structures of Knee in Osteoarthritis: A Gene Expression-Based Study.BioMed research international · 2020Article
- Glucosamine promotes chondrocyte proliferation via the Wnt/β‑catenin signaling pathway.International journal of molecular medicine · 2018Article
- Global transcriptome analysis to identify critical genes involved in the pathology of osteoarthritis.Bone & joint research · 2018Article
- Article
- A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine.Scientific reports · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of osteoarthritis (OA) treatment is not only control of symptoms (i.e. reducing pain and improving function) but also to preserve joint structure and maintain quality of life. OA management remains challenging. Glucosamine and chondroitin are two compounds available for treatment of OA patients. Taken alone or in combination, they have a good safety profile and a variety of effects. In-vitro and in-vivo experiments have revealed that both compounds induced key intermediates in the OA pathophysiological process. Clinical trials, although providing conflicting and questionable results, report symptomatic and structure-modifying effects for both pharmaceutical-grade compounds. This review will discuss all these subjects and emphasize the importance of the quality of tested compounds for achieving high quality clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.